Deutsche Bank AG Has $1.48 Million Stake in Kymera Therapeutics, Inc. $KYMR

Key Points

• Deutsche Bank AG reduced its stake in Kymera Therapeutics by 25.4%, now holding 54,007 shares valued at approximately $1.48 million after selling 18,435 shares in the first quarter.
• Despite the stake reduction, other institutional investors such as Price T Rowe Associates and Vanguard Group have increased their positions, showing mixed sentiment among institutional investors.
• Kymera Therapeutics reported a loss of $0.95 EPS for the last quarter, missing estimates, with revenue falling 55.1% year-over-year to $11.48 million.

Deutsche Bank AG decreased its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 25.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 54,007 shares of the company's stock after selling 18,435 shares during the period. Deutsche Bank AG owned 0.08% of Kymera Therapeutics worth $1,478,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of KYMR. KBC Group NV raised its stake in shares of Kymera Therapeutics by 15.2% during the 1st quarter. KBC Group NV now owns 2,479 shares of the company's stock worth $68,000 after purchasing an additional 328 shares in the last quarter. State of Wyoming bought a new position in Kymera Therapeutics during the fourth quarter valued at approximately $45,000. GF Fund Management CO. LTD. acquired a new stake in Kymera Therapeutics in the fourth quarter valued at approximately $55,000. GSA Capital Partners LLP lifted its stake in Kymera Therapeutics by 6.8% in the first quarter. GSA Capital Partners LLP now owns 31,537 shares of the company's stock valued at $863,000 after acquiring an additional 1,997 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Kymera Therapeutics by 7.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,960 shares of the company's stock worth $1,163,000 after acquiring an additional 2,011 shares in the last quarter.

Kymera Therapeutics Trading Down 4.6%

KYMR traded down $2.04 on Wednesday, hitting $41.83. 348,666 shares of the stock traded hands, compared to its average volume of 737,053. The business has a fifty day moving average price of $44.02 and a two-hundred day moving average price of $36.67. Kymera Therapeutics, Inc. has a 52 week low of $19.44 and a 52 week high of $53.27. The firm has a market capitalization of $2.99 billion, a PE ratio of -12.06 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.The firm had revenue of $11.48 million during the quarter, compared to the consensus estimate of $17.37 million. During the same period last year, the business earned ($0.58) earnings per share. The firm's revenue for the quarter was down 55.1% compared to the same quarter last year. On average, equities research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Analysts Set New Price Targets

KYMR has been the subject of several analyst reports. BTIG Research reaffirmed a "buy" rating and issued a $59.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, June 26th. Oppenheimer reissued an "outperform" rating and set a $53.00 price objective (down previously from $56.00) on shares of Kymera Therapeutics in a report on Friday, June 27th. The Goldman Sachs Group upgraded Kymera Therapeutics to a "strong-buy" rating in a report on Tuesday, July 15th. Bank of America upgraded Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price target on the stock in a report on Monday, June 2nd. Finally, B. Riley raised shares of Kymera Therapeutics to a "strong-buy" rating and set a $60.00 price target on the stock in a research report on Wednesday, July 30th. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $58.76.

Insider Activity at Kymera Therapeutics

In related news, Director Bros. Advisors Lp Baker acquired 655,500 shares of the firm's stock in a transaction on Monday, June 30th. The shares were bought at an average cost of $44.00 per share, with a total value of $28,842,000.00. Following the completion of the acquisition, the director owned 6,117,295 shares of the company's stock, valued at $269,160,980. This trade represents a 12.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Nello Mainolfi sold 30,000 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total value of $1,470,000.00. Following the completion of the sale, the chief executive officer owned 660,482 shares in the company, valued at approximately $32,363,618. This represents a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 48,349 shares of company stock worth $2,334,301 in the last ninety days. Company insiders own 16.01% of the company's stock.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.